Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
REVENUES    
Neurometric Information Services $ 111,400 $ 136,100
Clinical Services 634,500 502,400
Sales Revenue, Services, Net 745,900 638,500
OPERATING EXPENSES:    
Cost of Neurometric Service revenues 147,100 135,100
Research 482,800 738,800
Product development 442,000 381,700
Sales and marketing 1,231,500 870,900
General and administrative 4,271,900 5,017,000
Total operating expenses 6,575,300 7,143,500
OPERATING LOSS (5,829,400) (6,505,000)
OTHER INCOME (EXPENSE):    
Interest income (expense), net (7,567,000) (360,500)
Loss on extinguishment of debt (1,968,000) (1,094,300)
Financing fees (348,600) (213,400)
Offering costs (437,800) 0
Other non-operating income 458,800 0
Gain on derivative liabilities 6,826,700 0
Total other income (expense) (3,035,900) (1,668,200)
LOSS BEFORE PROVISION FOR INCOME TAXES (8,865,300) (8,173,200)
PROVISION FOR INCOME TAXES 1,300 800
NET LOSS $ (8,866,600) $ (8,174,000)
BASIC NET LOSS PER SHARE (in dollars per share) $ (0.16) $ (0.16)
DILUTED NET LOSS PER SHARE (in dollars per share) $ (0.16) $ (0.16)
WEIGHTED AVERAGE SHARES OUTSTANDING:    
Basic (in shares) 56,071,120 52,277,119
Diluted (in shares) 56,071,120 52,277,119